AbbVie, Inc.AbbVie, Inc.AbbVie, Inc.

AbbVie, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪317.45 B‬EUR
1.79EUR
‪4.09 B‬EUR
‪54.42 B‬EUR
‪1.76 B‬
Beta (1Y)
0.36
Employees (FY)
‪55 K‬
Change (1Y)
‪+5 K‬ +10.00%
Revenue / Employee (1Y)
‪989.41 K‬EUR
Net income / Employee (1Y)
‪74.43 K‬EUR

About AbbVie Inc.


CEO
Robert A. Michael
Website
Headquarters
North Chicago
Founded
2011
ISIN
US00287Y1091
FIGI
BBG00FZMGBN2
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Check out other big names from the same industry as 4AB.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
ABBV6009613
AbbVie Inc. 5.6% 15-MAR-2055
Yield to maturity
Maturity date
Mar 15, 2055
ABBV5068387
AbbVie Inc. 4.25% 21-NOV-2049
Yield to maturity
Maturity date
Nov 21, 2049
ABBV5759202
AbbVie Inc. 4.95% 15-MAR-2031
Yield to maturity
Maturity date
Mar 15, 2031
ABBV6009612
AbbVie Inc. 4.875% 15-MAR-2030
Yield to maturity
Maturity date
Mar 15, 2030
ABBV5759203
AbbVie Inc. 5.05% 15-MAR-2034
Yield to maturity
Maturity date
Mar 15, 2034
ABBV5068388
AbbVie Inc. 4.625% 01-OCT-2042
Yield to maturity
Maturity date
Oct 1, 2042
ABBV5758813
AbbVie Inc. 4.8% 15-MAR-2027
Yield to maturity
Maturity date
Mar 15, 2027
ABBV6009611
AbbVie Inc. 4.65% 15-MAR-2028
Yield to maturity
Maturity date
Mar 15, 2028
ABBV5759204
AbbVie Inc. 5.35% 15-MAR-2044
Yield to maturity
Maturity date
Mar 15, 2044
ABBV5068386
AbbVie Inc. 4.05% 21-NOV-2039
Yield to maturity
Maturity date
Nov 21, 2039
ABBV5068389
AbbVie Inc. 4.85% 15-JUN-2044
Yield to maturity
Maturity date
Jun 15, 2044

See all 4AB bonds 

Frequently Asked Questions


The current price of 4AB is 181.60 EUR — it has increased by 0.33% in the past 24 hours. Watch AbbVie, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange AbbVie, Inc. stocks are traded under the ticker 4AB.
4AB stock has risen by 0.56% compared to the previous week, the month change is a 9.10% rise, over the last year AbbVie, Inc. has showed a 2.03% increase.
We've gathered analysts' opinions on AbbVie, Inc. future price: according to them, 4AB price has a max estimate of 218.47 EUR and a min estimate of 145.65 EUR. Watch 4AB chart and read a more detailed AbbVie, Inc. stock forecast: see what analysts think of AbbVie, Inc. and suggest that you do with its stocks.
4AB reached its all-time high on Mar 4, 2025 with the price of 204.60 EUR, and its all-time low was 43.61 EUR and was reached on Oct 23, 2015. View more price dynamics on 4AB chart.
See other stocks reaching their highest and lowest prices.
4AB stock is 1.79% volatile and has beta coefficient of 0.36. Track AbbVie, Inc. stock price on the chart and check out the list of the most volatile stocks — is AbbVie, Inc. there?
Today AbbVie, Inc. has the market capitalization of ‪317.45 B‬, it has increased by 0.82% over the last week.
Yes, you can track AbbVie, Inc. financials in yearly and quarterly reports right on TradingView.
AbbVie, Inc. is going to release the next earnings report on Oct 24, 2025. Keep track of upcoming events with our Earnings Calendar.
4AB earnings for the last quarter are 2.52 EUR per share, whereas the estimation was 2.44 EUR resulting in a 3.12% surprise. The estimated earnings for the next quarter are 2.78 EUR per share. See more details about AbbVie, Inc. earnings.
AbbVie, Inc. revenue for the last quarter amounts to ‪13.09 B‬ EUR, despite the estimated figure of ‪12.76 B‬ EUR. In the next quarter, revenue is expected to reach ‪13.28 B‬ EUR.
4AB net income for the last quarter is ‪787.78 M‬ EUR, while the quarter before that showed ‪1.18 B‬ EUR of net income which accounts for −33.21% change. Track more AbbVie, Inc. financial stats to get the full picture.
Yes, 4AB dividends are paid quarterly. The last dividend per share was 1.41 EUR. As of today, Dividend Yield (TTM)% is 3.08%. Tracking AbbVie, Inc. dividends might help you take more informed decisions.
AbbVie, Inc. dividend yield was 3.54% in 2024, and payout ratio reached 263.15%. The year before the numbers were 3.87% and 220.33% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Sep 2, 2025, the company has ‪55 K‬ employees. See our rating of the largest employees — is AbbVie, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AbbVie, Inc. EBITDA is ‪22.71 B‬ EUR, and current EBITDA margin is 44.40%. See more stats in AbbVie, Inc. financial statements.
Like other stocks, 4AB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AbbVie, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AbbVie, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AbbVie, Inc. stock shows the strong buy signal. See more of AbbVie, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.